Alzheimer’s Disease Market

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the Alzheimer’s disease market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to Alzheimer’s disease and its associated symptoms. The chapter features a detailed discussion on the causes of disease, stages of disease progression, factors influencing the onset and progression of the disease, and the different pharmacological and non-pharmacological interventions intended for the treatment of this condition. The chapter includes information on the epidemiology of the disease, highlighting the diverse initiatives / programs led by the National Institutes of Health (NIH). Additionally, the chapter provides an overview of digital biomarkers and their use in the management of Alzheimer’s disease.

Chapter 4 provides detailed review of the current market landscape of drugs developed for the treatment of Alzheimer’s, including analyses based on several relevant parameters, such as current status of development (marketed, clinical and pre-clinical), phase of development (phase IV, phase III, phase II/III, phase II, phase I/II and phase I) of lead candidates, type of biologic (antibodies, peptides, cell and gene therapy, protein and vaccines), target disease stage (early stage, mild stage, mild to moderate stage and moderate to severe stage), type of treatment (symptomatic treatment, disease modifying treatment and both), mechanism of action (inhibitor, activator and modulator), route of administration (oral, intravenous, subcutaneous and others), dosing frequency (single dose, daily, twice daily, thrice daily, weekly, biweekly, monthly) type of therapy (monotherapy and combination therapy) and path to clinic (dedicated, repositioned and repurposed). Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.

Chapter 5 features detailed profiles of the key stakeholders involved in the development of therapeutics for Alzheimer’s disease. Each profile features a brief overview of the company, its financial information, details on its product portfolio, and recent developments and an informed future outlook.

Chapter 6 features a detailed assessment of over 110 discontinued drugs and terminated trials, providing information on the year of discontinuation, reason(s) for discontinuation, phase of discontinuation, mechanism of action of the terminated drugs, type of indication, reason for termination, affiliated stakeholders. In addition, the chapter presents a list of about 180 terminated clinical trials along with information on the year of termination and the key geographies across which these trials were being conducted. 

Chapter 7 provides a detailed review of around 20,000 peer-reviewed, scientific articles related to research on Alzheimer’s disease, which have been published between 2017 and June 2021, including analysis based on parameters, such as year of publication, key focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).

Chapter 8 features an analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2021, covering product development and commercialization agreements, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers and acquisitions, clinical trial agreements and other relevant types of deals. 

Chapter 9 presents a review of the funding and investments made in the domain, in the period between 2017 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 10 provides an in-depth analysis of analysis of more than 5,600 grants that have been awarded to various research institutes for projects related to Alzheimer’s disease, in the period between 2017 and 2021, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers. 

Chapter 11 provides a detailed analysis of more than 2,000 completed and ongoing clinical studies of therapies being developed for the treatment of Alzheimer’s, based on parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, target indication(s), focus areas, target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 12 provides an overview of the various patents that have been filed / granted, since 2017, based on various parameters, such as publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry players (in terms of number of patents filed). In addition, the chapter also features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 

Chapter 13 provides information on the various non-pharmacological interventions, including cognition / emotion-oriented therapies, sensory simulation therapies and other psychological interventions. The chapter presents a list of companies that offer such solutions, providing information on the devices / products and their mechanisms of action / working principles. In addition, the chapter includes a list of novel diagnostic techniques, which are claimed to be capable of assisting in timely diagnosis.

Chapter 14 includes an insightful market forecast analysis, highlighting growth opportunities of Alzheimer’s disease market till the year 2030. In addition, we have provided inputs on the likely distribution of the market opportunity based on different type of treatment (symptomatic and disease modifying treatment), symptomatic indications (dementia, insomnia and other psychological symptoms) and key geographical regions (North America, Europe and Asia-Pacific). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 15 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the Alzheimer’s disease market.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented the details of interviews held with (in alphabetical order) Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics), Mathias Schmidt, (Chief Executive Officer, ArmaGen) and Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International).

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. An Overview of Alzheimer’s Disease
3.1.1. Alzheimer’s Disease: Signs and Symptoms
3.1.2. Causes of Alzheimer’s Disease
3.1.3. Stages of Alzheimer’s Disease
3.2. Alzheimer’s Disease Management: Programs Undertaken by The National Institutes of Health
3.3. Alzheimer’s Disease Management
3.4. Digital Biomarkers in Alzheimer’s Disease
3.4.1. Potential of Digital Biomarkers in Alzheimer’s Disease
3.4.2. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer’s Disease

4. PIPELINE REVIEW: MARKETED AND CLINICAL- STAGE DRUGS
4.1. Analysis Methodology and Key Parameters
4.2. Alzheimer’s Disease Therapies: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Disease Stage 
4.2.4. Analysis by Type of Treatment
4.2.5. Analysis by Mechanism of Action 
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.2.8. Analysis by Type of Therapy
4.2.9. Analysis by Path to Clinic
4.2.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy

4.4. Alzheimer’s Disease Therapies: List of Developers
4.4.1. Analysis by Year of Establishment 
4.4.2. Analysis by Company Size and Geographical Location of Headquarters
4.4.3. Leading Players: Analysis by Number of Therapies
4.4.4. Analysis by Geography 

5. COMPANY PROFILES
5.1. AbbVie
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook

5.2. AC Immune
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Biogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Eisai
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. Eli Lilly and Company
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. GlaxoSmithKline 
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. Grifols
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Janssen Pharmaceutical
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook

5.9. Neurim Pharmaceuticals
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook

5.10. Novartis
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Product Portfolio
5.10.4. Recent Developments and Future Outlook

5.11. Novo Nordisk
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Product Portfolio
5.11.4. Recent Developments and Future Outlook

5.12. Roche
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Product Portfolio
5.12.4. Recent Developments and Future Outlook

5.13. Takeda Pharmaceutical
5.13.1. Company Overview
5.13.2. Financial Information
5.13.3. Product Portfolio
5.13.4. Recent Developments and Future Outlook

6. CASE STUDY: TERMINATED DRUGS 
6.1. Chapter Overview
6.2. Alzheimer’s Disease Therapies: List of Terminated Drugs
6.2.1. Analysis by Year of Discontinuation
6.2.2. Analysis by Phase of Discontinuation
6.2.3. Analysis by Mechanism of Action
6.2.4. Analysis by Type of Indication
6.2.5. Analysis by Reason for Termination
6.2.6. Analysis by Affiliated Stakeholders 
6.3. Alzheimer’s Disease Therapies: List of Terminated Clinical Trials
6.3.1. Distribution by Study Start Year and Year of Termination of Clinical Trials
6.3.2. Analysis by Location of Trials
6.4. Concluding Remarks

7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters 
7.2. Alzheimer’s Disease: List of Publications
7.3. Analysis by Year of Publication
7.4. Analysis by Key Focus Area
7.5. Word Cloud of Study Titles
7.6. Top Journal: Analysis by Number of Publications
7.6. Top Author: Analysis by Number of Publications

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Analysis Methodology and Key Parameters
8.2. Partnership Models
8.3. Alzheimer’s Disease: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partnership and Focus Area of Partnership
8.3.4. Analysis by Type of Partnership and Type of Molecule
8.3.5. Most Active Players: Analysis by Number of Partnerships 
8.3.6. Regional Analysis 
8.3.7. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Types of Funding
9.3. Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4 Analysis by Amount Invested Across Different Types of Molecules
9.3.5 Analysis by Amount Invested Across Different Types of Mechanism of Action
9.3.6. Regional Analysis by Amount Invested
9.3.7. Most Active Players: Analysis by Number of Funding Instances 
9.3.8. Most Active Investors: Analysis by Amount Funded

10. GRANT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Alzheimer’s Disease: List of Academic Grants
10.2.1. Analysis by Year of Grant Award
10.2.2. Analysis by Grant Amount Awarded
10.2.3. Analysis by Administering Institute Center
10.2.4. Analysis by Support Period
10.2.5. Analysis by Administering Institute Center and Support Year
10.2.6. Analysis by Type of Grant Application
10.2.7. Analysis by Grant Activity Code
10.2.8. Word Cloud of Study Titles
10.2.9. Analysis by Purpose of Grant Award
10.2.10. Analysis by Type of Recipient Organization
10.2.11. Popular NIH Departments: Analysis by Number of Grants
10.2.12. Prominent Program Officers: Analysis by Number of Grants

11. CLINICAL TRIAL ANALYSIS
11.1. Analysis Methodology and Key Parameters 
11.2. Alzheimer’s Disease: Clinical Trial Analysis
11.3.1. Analysis by Trial Status 
11.3.2. Analysis by Trial Registration Year 
11.3.3. Analysis by Type of Sponsor / Collaborator
11.3.3. Analysis by Type of Study Design
11.3.4. Analysis by Registration Year and Type of Study
11.3.5. Analysis by Patient Enrollment
11.3.6. Year-wise Trend of Completed and Recruiting Trials 
11.3.7. Analysis by Age Category
11.3.8. Word Cloud of Study Titles
11.3.9. Most Active Industry Players: Analysis by Number of Registered Trials 
11.3.10. Most Active Non- Industry Players: Analysis by Number of Registered Trials 
11.3.11. Analysis by Trial Location
11.3.12. Analysis by Trial Status and Geography

12. PATENT ANALYSIS
12.1. Analysis Methodology and Key Parameters
12.2. Alzheimer’s Disease: Patent Analysis
12.2.1. Analysis by Patent Application Year
12.2.2. Analysis by Geography
12.2.3. Analysis by CPC Symbols
12.2.4. Word Cloud: Emerging Focus Areas
12.2.5. Analysis by Type of Applicant
12.2.6. Leading Players: Analysis by Number of Patents
12.2.7 Leading Players: Analysis by Number of International Patents
12.2.8. Patent Valuation Analysis

13. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS
13.1. Non-Pharmacological Interventions for Alzheimer’s Disease
13.1.1. Cognition / Emotion-Oriented Interventions
13.1.1.1. Reminiscence Therapy
13.1.1.2. Simulated Presence Therapy

13.1.2. Sensory Stimulation-based Interventions
13.1.2.1. Virtual Reality
13.1.2.2. Music Therapy
13.1.2.3. Light Therapy
13.1.2.4. Aromatherapy
13.1.2.5. Reflexology
13.1.3. Other Psycho-social Interventions
13.1.3.1. Animal-Assisted Therapy

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Forecast Methodology and Key Assumptions
14.2. Global Alzheimer’s Disease Market, 2021-2030
14.3. Global Alzheimer’s Disease Market, 2021-2030: Distribution by Type of Treatment
14.4. Global Alzheimer’s Disease Market, 2021-2030: Distribution by Type of Target Disease Indication
14.5. Global Alzheimer’s Disease Market, 2021-2030: Distribution by Geography
14.5.1. Alzheimer’s Disease Market in North America, 2021-2030
14.5.1.1. Alzheimer’s Disease Market in North America, 2021-2030: Distribution by Type of Treatment
14.5.1.1.1. Alzheimer’s Disease Market in North America, 2021-2030: Distribution by Symptomatic Treatment
14.5.1.1.1.1. Alzheimer’s Disease Market in North America, 2021-2030: Share of Dementia in Symptomatic Treatment Market
14.5.1.1.1.2. Alzheimer’s Disease Market in North America, 2021-2030: Share of Insomnia in Symptomatic Treatment Market
14.5.1.1.1.3. Alzheimer’s Disease Market in North America, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market

14.5.1.1.2. Alzheimer’s Disease Market in North America, 2021-2030: Distribution by Disease Modifying Treatment

14.5.2. Alzheimer’s Disease Market in Europe, 2021-2030
14.5.2.1. Alzheimer’s Disease Market in Europe, 2021-2030: Distribution by Type of Treatment
14.5.2.1.1. Alzheimer’s Disease Market in Europe, 2021-2030: Distribution by Symptomatic Treatment
14.5.2.1.1.1. Alzheimer’s Disease Market in Europe, 2021-2030: Share of Dementia in Symptomatic Treatment Market
14.5.2.1.1.2. Alzheimer’s Disease Market in Europe, 2021-2030: Share of Insomnia in Symptomatic Treatment Market
14.5.2.1.1.3. Alzheimer’s Disease Market in Europe, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market 
14.5.2.1.2. Alzheimer’s Disease Market in Europe, 2021-2030: Distribution by Disease Modifying Treatment

14.5.3. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030
14.5.3.1. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Distribution by Type of Treatment
14.5.3.1.1. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Distribution by Symptomatic Treatment
14.5.3.1.1.1. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Share of Dementia in Symptomatic Treatment Market
14.5.3.1.1.2. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Share of Insomnia in Symptomatic Treatment Market
14.5.3.1.1.3. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market
14.5.3.1.2. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Distribution by Disease Modifying Treatment

15.  CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS
16.1. Cognition Therapeutics
16.1.1. Company Snapshot
16.1.1. Interview Transcript: Kenneth Moch (President and Chief Executive Officer)

16.2. ArmaGen
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Mathias Schmidt (Chief Executive Officer)

16.2. ICB International
16.2.1. Company Snapshot
16.3.2. Interview Transcript: Ram Bhatt (Chief Executive Officer, Chairman and Founder)

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1. Overview of Alzheimer’s Disease
Figure 3.2. Alzheimer’s Disease: Signs and Symptoms
Figure 3.3. Causes of Alzheimer’s Disease
Figure 3.4. Stages of Alzheimer’s Disease
Figure 3.5. Alzheimer’s Disease Management: Programs Undertaken by The National Institutes of Health
Figure 3.6. Alzheimer’s Disease Management
Figure 3.7. Digital Biomarkers in Alzheimer’s Disease
Figure 3.8. Potential of Digital Biomarkers in Alzheimer’s Disease
Figure 3.9. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer’s Disease
Figure 4.1. Marketed and Clinical-Stage Drugs: Distribution by Phase of Development
Figure 4.2. Marketed and Clinical-Stage Drugs: Distribution by Type of Molecule
Figure 4.3. Marketed and Clinical-Stage Drugs: Distribution by Target Disease Stage
Figure 4.4. Marketed and Clinical-Stage Drugs: Distribution by Type of Treatment
Figure 4.5. Marketed and Clinical-Stage Drugs: Distribution by Mechanism of Action
Figure 4.6. Marketed and Clinical-Stage Drugs: Distribution by Route of Administration
Figure 4.7. Marketed and Clinical-Stage Drugs: Distribution by Dosing Frequency
Figure 4.8. Marketed and Clinical-Stage Drugs: Distribution by Type of Therapy
Figure 4.9. Marketed and Clinical-Stage Drugs: Distribution by Path to Clinic
Figure 4.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
Figure 4.11. Alzheimer’s Disease Therapies: List of Developers
Figure 4.12. Alzheimer’s Disease Therapy Developers: Distribution by Year of Establishment
Figure 4.13. Alzheimer’s Disease Therapy Developers: Distribution by Company Size and Geographical Location of Headquarters
Figure 4.14. Leading Players: Distribution by Number of Therapies
Figure 4.15. Alzheimer’s Disease Therapy Developers: Distribution by Geography 
Figure 5.1. AbbVie: Financial Information
Figure 5.2. AC Immune: Financial Information
Figure 5.3. Biogen: Financial Information
Figure 5.4. Eisai: Financial Information
Figure 5.5. Eli Lilly and Company: Financial Information
Figure 5.6. GlaxoSmithKline: Financial Information
Figure 5.7. Grifols: Financial Information
Figure 5.8. Janssen Pharmaceutical: Financial Information
Figure 5.9. Neurim Pharmaceuticals: Financial Information
Figure 5.10. Novartis: Financial Information
Figure 5.11. Novo Nordisk: Financial Information
Figure 5.12. Roche: Financial Information
Figure 5.13. Takeda Pharmaceutical: Financial Information
Figure 6.1. Terminated Drugs: Distribution by Year of Discontinuation
Figure 6.2. Terminated Drugs: Distribution by Phase of Discontinuation
Figure 6.3. Terminated Drugs: Distribution by Mechanism of Action
Figure 6.4. Terminated Drugs: Distribution by Type of Indication
Figure 6.5. Terminated Drugs: Distribution by Reason for Termination
Figure 6.6. Terminated Drugs: Distribution by Affiliated Stakeholders 
Figure 6.7. Terminated Drugs: Distribution by Study Start Year and Year of Termination of Clinical Trials
Figure 6.8. Terminated Drugs: Distribution by Location of Trials
Figure 7.1. Publication Analysis: Distribution by Year of Publication
Figure 7.2. Publication Analysis: Distribution by Key Focus Area
Figure 7.3. Publication Analysis: Word Cloud of Study Titles
Figure 7.4. Top Journals: Distribution by Number of Publications
Figure 7.5. Top Authors: Distribution by Number of Publications
Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area of Partnership
Figure 8.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Molecule
Figure 8.5. Most Active Players: Distribution by Number of Partnerships 
Figure 8.6. Partnerships and Collaborations: Regional Distribution 
Figure 8.7. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1. Funding and Investment Analysis: Distribution by Year of Investment
Figure 9.2. Funding and Investment Analysis: Distribution by Amount Invested
Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.4. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Molecules
Figure 9.5. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Mechanism of Action
Figure 9.6. Funding and Investment Analysis: Regional Distribution by Amount Invested
Figure 9.7. Most Active Players: Distribution by Number of Funding Instances 
Figure 9.8. Most Active Investors: Distribution by Amount Funded
Figure 10.1. Grant Analysis: Distribution by Year of Grant Award
Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded
Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
Figure 10.4. Grant Analysis: Distribution by Support Period
Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Year
Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
Figure 10.8. Grant Analysis: Word Cloud of Study Titles
Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
Figure 10.10. Grant Analysis: Distribution by Type of Recipient Organization
Figure 10.11. Popular NIH Departments: Distribution by Number of Grants
Figure 10.12. Prominent Program Officers: Distribution by Number of Grants 
Figure 11.1. Clinical Trial Analysis: Distribution by Trial Status 
Figure 11.2. Clinical Trial Analysis: Distribution by Trial Registration Year 
Figure 11.3. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.4. Clinical Trial Analysis: Distribution by Type of Study Design
Figure 11.5. Clinical Trial Analysis: Distribution by Registration Year and Type of Study
Figure 11.6. Clinical Trial Analysis: Distribution by Patient Enrollment
Figure 11.7. Clinical Trial Analysis: Year-wise Trend of Completed and Recruiting Trials
Figure 11.8. Clinical Trial Analysis: Distribution by Age Category
Figure 11.9. Clinical Trial Analysis: Word Cloud of Study Titles
Figure 11.10. Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.11. Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.12. Clinical Trial Analysis: Distribution by Trial Location
Figure 11.13. Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 12.1. Patent Analysis: Distribution by Patent Application Year
Figure 12.2. Patent Analysis: Distribution by Geography
Figure 12.3. Patent Analysis: Distribution by CPC Symbols
Figure 12.4. Word Cloud: Emerging Focus Areas
Figure 12.5. Patent Analysis: Distribution by Type of Applicant
Figure 12.6. Leading Players: Distribution by Number of Patents
Figure 12.7 Leading Players: Distribution by Number of International Patents
Figure 12.8. Patent Analysis: Patent Valuation Analysis
Figure 13.1. Non-Pharmacological Interventions for Alzheimer’s Disease
Figure 13.2. Cognition / Emotion-Oriented Interventions
Figure 13.3. Reminiscence Therapy
Figure 13.4. Simulated Presence Therapy
Figure 13.5. Sensory Stimulation-based Interventions
Figure 13.6. Virtual Reality
Figure 13.7. Music Therapy
Figure 13.8. Light Therapy
Figure 13.9. Aromatherapy
Figure 13.10. Reflexology
Figure 13.11. Other Psycho-social Interventions
Figure 13.12. Animal-Assisted Therapy
Figure 14.1. Global Alzheimer’s Disease Market, 2021-2030 (USD Million)
Figure 14.2. Global Alzheimer’s Disease Market, 2021-2030: Distribution by Type of Treatment (USD Million)
Figure 14.3. Global Alzheimer’s Disease Market, 2021-2030: Distribution by Type of Target Disease Indication (USD Million)
Figure 14.4. Global Alzheimer’s Disease Market, 2021-2030: Distribution by Geography (USD Million)
Figure 14.5. Alzheimer’s Disease Market in North America, 2021-2030 (USD Million)
Figure 14.6. Alzheimer’s Disease Market in North America, 2021-2030: Distribution by Type of Treatment (USD Million)
Figure 14.7. Alzheimer’s Disease Market in North America, 2021-2030: Distribution by Symptomatic Treatment (USD Million)
Figure 14.8. Alzheimer’s Disease Market in North America, 2021-2030: Share of Dementia in Symptomatic Treatment Market (USD Million)
Figure 14.9. Alzheimer’s Disease Market in North America, 2021-2030: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Figure 14.10. Alzheimer’s Disease Market in North America, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Figure 14.11. Alzheimer’s Disease Market in North America, 2021-2030: Distribution by Disease Modifying Treatment (USD Million)
Figure 14.12. Alzheimer’s Disease Market in Europe, 2021-2030 (USD Million)
Figure 14.13. Alzheimer’s Disease Market in Europe, 2021-2030: Distribution by Type of Treatment (USD Million)
Figure 14.14. Alzheimer’s Disease Market in Europe, 2021-2030: Distribution by Symptomatic Treatment (USD Million)
Figure 14.15. Alzheimer’s Disease Market in Europe, 2021-2030: Share of Dementia in Symptomatic Treatment Market (USD Million)
Figure 14.16. Alzheimer’s Disease Market in Europe, 2021-2030: Share of Insomnia in Symptomatic Treatment Market (USD Million)
Figure 14.17. Alzheimer’s Disease Market in Europe, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
Figure 14.18. Alzheimer’s Disease Market in Europe, 2021-2030: Distribution by Disease Modifying Treatment (USD Million)
Figure 14.19. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030(USD Million)
Figure 14.20. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Distribution by Type of Treatment (USD Million)
Figure 14.21. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Distribution by Symptomatic Treatment (USD Million)
Figure 14.22. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Share of Dementia in Symptomatic Treatment (USD Million)
Figure 14.23. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Share of Insomnia in Symptomatic Treatment (USD Million)
Figure 14.24. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment (USD Million)
Figure 14.25. Alzheimer’s Disease Market in Asia-Pacific, 2021-2030: Distribution by Disease Modifying Treatment (USD Million)

List Of Tables

Table 4.1 Alzheimer’s Disease: Marketed and Clinical Development Pipeline
Table 4.2 Alzheimer’s Disease Therapies: List of Developers
Table 6.1 Alzheimer’s Disease Therapies: List of Terminated Drugs
Table 7.1 Alzheimer’s Disease: List of Publications
Table 8.1 Alzheimer’s Disease: List of Partnerships and Collaborations
Table 9.1 Alzheimer’s Disease: List of Funding and Investments
Table 10.1 Alzheimer’s Disease: List of Academic Grants
Table 11.1 Alzheimer’s Disease: List of Clinical Trials
Table 12.1 Alzheimer’s Disease: List of Patents

List Of Companies

The following companies and organizations have been mentioned in the report.

1. AB Science
2. AbbVie
3. AC Immune
4. ACADIA Pharmaceuticals
5. Acelot
6. Actinogen Medical
7. Acumen Pharmaceuticals
8. AFFiRiS 
9. AgeneBio 
10. Alector
11. Alkahest
12. Allergan (part of AbbVie)
13. Allinky Biopharma
14. Alterity Therapeutics (formerly known as Prana Biotechnology)
15. Alzheimer's Association
16. Alzheimer's Disease Cooperative Study (ADCS)
17. Alzinova 
18. Alzprotect
19. American Life Science Pharmaceuticals (ALSP)
20. Amylyx Pharmaceuticals
21. Anavex Life Sciences
22. Aphios
23. APRINOIA Therapeutics
24. Archer Pharmaceuticals
25. Ariana Pharma
26. AriBio
27. ArmaGen (acquired by JCR Pharmaceuticals)
28. ARMGO Pharma
29. Asceneuron
30. AstraZeneca
31. Athira Pharma (formerly known as M3 Biotechnology)
32. Atridia
33. Ausio Pharmaceuticals
34. Autifony Therapeutics
35. Avanir Pharmaceuticals
36. Avid Radiopharmaceuticals
37. Axon Neuroscience
38. Axsome Therapeutics
39. AZTherapies
40. Banner Alzheimer's Institute
41. Bausch Health
42. Beacon Biosignals
43. BELLUS Health 
44. BioArctic 
45. Biogen
46. Biohaven
47. Bionomics
48. BioVie
49. Bristol Myers Squibb
50. Cambridge Quantum Computing (CQC)
51. Cassava Sciences (formerly known as Pain Therapeutics)
52. Celgene 
53. Cenna Biosciences
54. CEOi
55. Cerecin (formerly Accera)
56. CereSpir
57. CHA Biotech 
58. Chang Gung Memorial Hospital (CGMH)
59. Changchun Huayang High-tech
60. Chaperone Therapeutics
61. Charsire Biotechnology
62. Cogentis Therapeutics
63. Cognition Therapeutics
64. Cognosci
65. CoMentis
66. Corium International
67. Cortexyme
68. CuraSen Therapeutics
69. Cure Alzheimer's Fund
70. Cure Network Dolby Acceleration Partners (CNDAP)
71. Cyclerion Therapeutics
72. DAE HWA Pharmaceutical
73. Denali Therapeutics
74. Denovo Biopharma
75. Edunn Biotechnology
76. EIP Pharma
77. Eisai
78. Eli Lilly
79. E-Scape Bio
80. Evidation
81. ExonHit Therapeutics (part of Sofinnova Partners)
82. FUJIFILM Toyama Chemical
83. GemVax & Kael
84. Genentech
85. Genervon Biopharmaceuticals
86. Genzyme
87. Gismo Therapeutics
88. GlaxoSmithKline
89. GliaCure
90. GliaPharm
91. Grifols
92. HSRx Biopharmaceutical
93. Hyundai Pharm
94. IlDong Pharmaceutical
95. Imeka
96. INmune Bio 
97. Innovative California Biosciences International
98. IntelGenx
99. Intellect Neurosciences
100. Intra-Cellular Therapies
101. Ionis Pharmaceuticals
102. IXICO
103. Janssen Pharmaceuticals
104. Johns Hopkins University
105. KalGene Pharmaceuticals
106. Karuna Pharmaceuticals
107. Konkuk University Medical Center (KUMC)
108. K-PAX Pharmaceuticals
109. Kyowa Hakko Kirin 
110. Libella Gene Therapeutics
111. Lipopharma
112. Longeveron
113. Lundbeck
114. Lyndra Therapeutics
115. MD Anderson Cancer Center
116. Medesis Pharma 
117. Medipost
118. Medpace
119. Merck Sharp & Dohme 
120. Metabolic Solutions Development.
121. Mission Therapeutics
122. Mylan
123. National Institute of Mental Health (NIMH)
124. National Institute on Aging (NIA)
125. National Institutes of Health (NIH)
126. National Research Council Canada
127. Nature Cell 
128. Neuralstem 
129. Neurim Pharmaceuticals
130. NeuroActiva
131. Neurocentria
132. Neurodon
133. NeuroGeneration
134. NeuroGenetic Pharmaceuticals
135. NeuroNascent
136. NeurOp
137. Neurotez
138. NIH Clinical Center (CC)
139. Novartis
140. Novo Nordisk
141. NYU Langone Health
142. Orion Pharma
143. Oryzon Genomics
144. Otsuka Pharmaceutical
145. P2D Bioscience 
146. Pfizer
147. PharmatrophiX
148. Pharmazz
149. Pharnext
150. Proclara Biosciences
151. Procter & Gamble
152. ProMIS Neurosciences
153. Prothena
154. QR Pharma
155. Regenera Pharma
156. RemeGenix
157. ReMYND
158. Reviva Pharmaceuticals
159. Roche
160. Sage Therapeutics
161. Sahlgrenska University Hospital
162. Sangamo Therapeutics
163. Sanofi
164. Selexis
165. Shahid Sadoughi University of Medical Sciences and Health Services
166. Shanghai Green Valley Pharmaceutical
167. Shape Therapeutics
168. Shionogi
169. Sierra Sciences
170. Sosei Heptares
171. St Vincent’s Institute of Medical Research (SVI)
172. Stemedica Cell Technologies
173. Suven Life Sciences
174. Synaptogenix (formerly Neurotrope Bioscience) 
175. T3D Therapeutics
176. Taipei Veterans General Hospital (TVGH)
177. Taiyo International
178. Takeda Pharmaceutical 
179. TauRx Therapeutics
180. Tetra Discovery Partners
181. THERANEXUS
182. Tonix Pharmaceuticals
183. Treventis 
184. TrueBinding
185. UCB
186. University of California
187. University of Kansas Medical Center (KUMC)
188. University of Oslo
189. University of Texas
190. VA Office of Research and Development (ORD)
191. Vaccinex
192. Vaxxinity (formerly known as United Neuroscience)
193. Vivoryon Therapeutics (formerly Probiodrug)
194. Voyager Therapeutics
195. VT BIO
196. Worldwide Clinical Trials
197. Wyeth
198. Xcelthera

Source 1: www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Alzheimer's%20disease%20is%20the%20most,60%E2%80%9370%25%20of%20cases
Source 2: www.biopharmadive.com/news/alzheimers-drugs-amyloid-biogen-aduhelm-approval/601483/